Publication
“AI and sustainability - cure or curse?”
While AI can help resolve data issues in sustainable investing, it can create problems such as information breaches and inherent bias in data.
Global | Publication | May 2017
Treaty/Act: CETA/Bill C-30 (An Act to implement the Comprehensive Economic and Trade Agreement between Canada and the European Union and its Member States and to provide for certain other measures)
Date: May 11, 2017 – Bill C-30 passes third reading in Senate
The overhaul to Canada’s pharmaceutical patent regime is nearly here. On May 11, 2017, the Canadian Senate passed Bill C-30 (the act intended to implement CETA into Canadian law) without amendment, the final major stage of the legislative process. Bill C-30 will become law once it receives royal assent, a formality.
As we reported, CETA and Bill C-30 provide key reforms to the Patent Act affecting the pharmaceutical industry, including:
We anticipate the details to be published shortly.
Are you CETA ready? Contact Norton Rose Fulbright with all your CETA questions.
Bill C-30, Third Reading (House of Commons)
Text of the final Comprehensive Economic and Trade Agreement
Publication
While AI can help resolve data issues in sustainable investing, it can create problems such as information breaches and inherent bias in data.
Publication
In this edition of Regulation Around the World we review recent steps that financial services regulatory authorities have taken as regards investment research.
Publication
The ongoing conflicts and further geopolitical tensions in Eastern Europe and the Middle East, coupled with upcoming elections in a number of key countries including the US and the UK, make 2024 challenging to predict what impact this will have on the insurance sector.
Subscribe and stay up to date with the latest legal news, information and events . . .
© Norton Rose Fulbright LLP 2023